Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

References

• 1  Ho L, Fivecoat H, Wang J, Pasinetti GM. Alzheimer’s disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp. Gerontol.45,15–22 (2010).
  Medline CASGoogle Scholar
• 2  Fortea J, Sala-Llonch R, Bartrés-Faz D et al. Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1–42 values have thicker cortex in Alzheimer’s disease vulnerable areas. Biol. Psychiatry70,183–190 (2011).
  Medline CASGoogle Scholar
• 3  Rami L, Sala-Llonch R, Solé-Padullés C et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer’s disease. J. Alzheimers Dis.30,1–10 (2012).
  MedlineGoogle Scholar
• 4  Jack CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet9,1–20 (2010).
  MedlineGoogle Scholar
• 5  Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci.20,415–455 (1973).
  Medline CASGoogle Scholar
• 6  Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J. Neurol. Sci.184,101–122 (2001).
  Medline CASGoogle Scholar
• 7  Teunissen C. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol. Aging23,485–508 (2002).
  Medline CASGoogle Scholar
• 8  Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol.6,131–144 (2010).
  Medline CASGoogle Scholar
• 9  Mulder C, Verwey NA, van der Flier WM et al. Amyloid-beta(1–42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem.56,248–253 (2010).
  Medline CASGoogle Scholar
• 10  Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7,257–262 (2011).
  MedlineGoogle Scholar
• 11  Ibáñez P, Bonnet A-M, Débarges B et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet364,1169–1171 (2004).
  Medline CASGoogle Scholar
• 12  Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol.10,230–240 (2011).
  Medline CASGoogle Scholar
• 13  Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain133,713–726 (2010).
  MedlineGoogle Scholar
• 14  Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov. Disord.26,1428–1435 (2011).
  MedlineGoogle Scholar
• 15  Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. doi:10.1097/WAD.0b013e31823899cc (2011) (Epub ahead of print).
  Google Scholar
• 16  Mattsson N, Andreasson U, Persson S et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement.7,386–395 e6 (2011).
  Medline CASGoogle Scholar
• 17  Sunderland T, Linker G, Mirza N et al. Decreased beta-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA289,2094–2103 (2003).
  MedlineGoogle Scholar
• 18  Mollenhauer B, El-Agnaf O, Marcus K, Trenkwalder C, Schlossmacher M. Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark. Med.4,683–699 (2010).
  CASGoogle Scholar
• 19  Verwey NA, van der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann. Clin. Biochem.46,235–240 (2009).
  Medline CASGoogle Scholar
• 20  Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett.409,1–4 (2006).
  Medline CASGoogle Scholar
• 21  Mattsson N, Zetterberg H, Blennow K. Lessons from multicenter studies on CSF biomarkers for Alzheimer’s disease. Int. J. Alzheimers. Dis.2010,1–5 (2010).
  Google Scholar
• 22  Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7,280–292 (2011).
  MedlineGoogle Scholar
• 23  Bjerke M, Portelius E, Minthon L et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimers. Dis.2010,1–11 (2010).
  Google Scholar
• 24  Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β((1–42)), tau, and phosphorylated tau in Alzheimer’s disease: report of an international workshop. Int. J. Alzheimers. Dis.2010,pii: 635053 (2010).
  Google Scholar
• 25  Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin. Chem. Lab. Med.44,750–759 (2006).
  Medline CASGoogle Scholar
• 26  Perret-Liaudet A, Pelpel M, Tholance Y et al. Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes. J. Alzheimers Dis.30,1–8 (2012).
  MedlineGoogle Scholar
• 27  Schoonenboom NSM, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid beta (1–42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem.51,189–195 (2005).
  Medline CASGoogle Scholar
• 28  Vanderstichele H, Bibl M, Engelborghs S et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement.8,65–73 (2012).
  Medline CASGoogle Scholar
• 29  Teunissen C, Petzold A, Bennett J et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology73,1914–1922 (2009).
  Medline CASGoogle Scholar
• 30  Murillo-Rodriguez E, Désarnaud F, Prospéro-García O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci.79,30–37 (2006).
  Medline CASGoogle Scholar
• 31  Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology68,666–669 (2007).
  Medline CASGoogle Scholar
• 32  Moghekar A, Goh J, Li M, Albert M, O’Brien RJ. Cerebrospinal fluid aβ and tau level fluctuation in an older clinical cohort. Arch. Neurol.69,246–250 (2012).
  MedlineGoogle Scholar
• 33  Slats D, Claassen JAHR, Spies PE et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer’s disease subjects and healthy older volunteers. Neurobiol. Aging33,831.e1–9 (2012).
  Medline CASGoogle Scholar
• 34  Frasier M, Chowdhury S, Sherer T et al. The Parkinson’s progression markers initiative: a prospective biomarker study. Mov. Disord.95(4),629–635 (2010).
  Google Scholar
• 35  Spies PE, Slats D, Rikkert MGO, Tseng J, Claassen JA, Verbeek MM. CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans. Neurosci. Lett.504,336–338 (2011).
  Medline CASGoogle Scholar
• 36  Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clinica Chimica Acta310,173–186 (2001).
  Medline CASGoogle Scholar
• 37  Simonsen AH, Bech S, Laursen I et al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J. Neurosci. Methods191,244–248 (2010).
  Medline CASGoogle Scholar
• 38  Blennow K, Fredman P, Wallin A, Gottfries CG, Långström G, Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur. Neurol.33,126–128 (1993).
  Medline CASGoogle Scholar
• 39  Blennow K, Wallin A, Gottfries CG, Månsson JE, Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J. Neural. Transm. Park. Dis. Dement. Sect.5,5–15 (1993).
  Medline CASGoogle Scholar
• 40  Mollenhauer B, Trautmann E, Otte B et al. α-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. doi:10.1007/s00702–012–0784–0780 (2012) (Epub ahead of print).
  MedlineGoogle Scholar
• 41  Kuntz KM, Kokmen E, Stevens JC, Miller P, Offord KP, Ho MM. Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology42,1884–1887 (1992).
  Medline CASGoogle Scholar
• 42  Netto CBO, Conte S, Leite MC et al. Serum S100B protein is increased in fasting rats. Arch. Med. Res.37,683–686 (2006).
  Medline CASGoogle Scholar
• 43  Lehmann S, Roche S, Allory Y et al. [Preanalytical guidelines for clinical proteomics investigation of biological fluids]. Ann. Biol. Clin. (Paris)67,629–639 (2009).
  Medline CASGoogle Scholar
• 44  Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D et al. Toward an Alzheimer’s disease diagnosis via high-resolution blood gene expression. Alzheimers Dement.6,25–38 (2010).
  Medline CASGoogle Scholar
• 45  Rye PD, Booij BB, Grave G et al. A novel blood test for the early detection of Alzheimer’s disease. J. Alzheimers Dis.23,121–129 (2011).
  Medline CASGoogle Scholar
• 46  Lewczuk P, Beck G, Esselmann H et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin. Chem.52,332–334 (2006).
  Medline CASGoogle Scholar
• 47  Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20. Clin. Chim. Acta411,1833 (2010).
  Medline CASGoogle Scholar
• 48  Petzold A, Sharpe LT, Keir G. Spectrophotometry for cerebrospinal fluid pigment analysis. Neurocrit. Care4,153–162 (2006).
  Medline CASGoogle Scholar
• 49  You J-S, Gelfanova V, Knierman MD, Witzmann FA, Wang M, Hale JE. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics5,290–296 (2005).
  Medline CASGoogle Scholar
• 50  Berven FS, Kroksveen AC, Berle M et al. Preanalytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin. Appl.1,699–711 (2007).
  Medline CASGoogle Scholar
• 51  Jimenez CR, Koel-Simmelink M, Pham TV, van der Voort L, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. Proteomics Clin. Appl.1,1385–1392 (2007).
  Medline CASGoogle Scholar
• 52  West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Schou C, Heegaard NHH. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem.77,5114–5123 (2005).
  Medline CASGoogle Scholar
• 53  Rosenling T, Slim CL, Christin C et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res.8,5511–5522 (2009).
  Medline CASGoogle Scholar
• 54  Kaiser E, Schönknecht P, Thomann P, Hunt A, Schröder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1–42). Neurosci. Lett.417,193–195 (2007).
  Medline CASGoogle Scholar
• 55  Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimers Dis.25,739–745 (2011).
  Medline CASGoogle Scholar
• 56  Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid. Methods (San Diego, Calif)56(4),514–518 (2012).
  Medline CASGoogle Scholar
• 57  Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol.12,505–523 (2007).
  Medline CASGoogle Scholar
• 58  Chaigneau C, Cabioch T, Beaumont K, Betsou F. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation. Clin. Chem. Lab. Med.45,1390–1395 (2007).
  Medline CASGoogle Scholar
• 59  Nishino S, Ripley B, Overeem S et al. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol.50,381–388 (2001).
  Medline CASGoogle Scholar
• 60  Botella-López A, Burgaya F, Gavín R et al. Reelin expression and glycosylation patterns are altered in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA103,5573–5578 (2006).
  Medline CASGoogle Scholar
• 61  Sjögren M, Vanderstichele H, Agren H et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin. Chem.47,1776–1781 (2001).
  Medline CASGoogle Scholar
• 62  Bibl M, Esselmann H, Otto M et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis25,2912–2918 (2004).
  Medline CASGoogle Scholar
• 63  Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez J-C. Truncated cystatin C in cerebrospiral fluid: technical [corrected] artefact or biological process? Proteomics5,3060–3065 (2005).
  Medline CASGoogle Scholar
• 64  Schipke CG, Jessen F, Teipel S et al. Long-term stability of Alzheimer’s disease biomarker proteins in cerebrospinal fluid. J. Alzheimers Dis.26,255–262 (2011).
  Medline CASGoogle Scholar